SLN NASDAQ
Silence Therapeutics plc
1W: -4.8%
1M: -28.1%
3M: +0.6%
YTD: +73.0%
1Y: +108.6%
3Y: +9.7%
5Y: -51.2%
$10.64
-0.07 (-0.65%)
Weekly Expected Move ±5.2%
$10
$10
$11
$11
$12
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$559K
-98.7% ▼
5Y CAGR: -36.7%
Gross Profit
$344K
-98.9% ▼
5Y CAGR: -27.5%
Operating Income
-$61M
-41.7% ▼
Net Income
-$89M
-95.6% ▼
EPS (Diluted)
$-1.89
+20.3% ▲
EBITDA
-$61M
-24.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12M | $22M | $25M | $43M | $559K |
| YoY Growth | +126.6% | +74.4% | +17.2% | +70.5% | -98.7% |
| Cost of Revenue | $7M | $13M | $10M | $12M | $215K |
| Gross Profit | $5M | $8M | $15M | $31M | $344K |
| Gross Margin | 39.9% | 37.8% | 59.3% | 72.7% | 61.5% |
| R&D Expenses | $31M | $44M | $44M | $68M | $68M |
| SG&A Expenses | $20M | $26M | $21M | $27M | $22M |
| Operating Expenses | $51M | $69M | $65M | $95M | $90M |
| Operating Income | -$46M | -$61M | -$50M | -$63M | -$61M |
| Operating Margin | -369.0% | -281.9% | -195.5% | -146.4% | -10950.8% |
| Interest Expense | $8K | $47K | $34K | $0 | $0 |
| Income Before Tax | -$46M | -$50M | -$50M | -$44M | -$89M |
| Tax Expense | -$6M | $688K | -$7M | $845K | $11K |
| Net Income | -$39M | -$50M | -$43M | -$45M | -$89M |
| Net Margin | -317.4% | -232.4% | -170.5% | -104.7% | -15851.9% |
| EPS (Diluted) | $-1.36 | $-3.81 | $-3.48 | $-2.37 | $-1.89 |
| EBITDA | -$45M | -$60M | -$50M | -$49M | -$61M |
| Shares Outstanding | 30M | 11M | 12M | 15M | 47M |